HCW Biologics Inc. Common Stock (HCWB)
Stock · NASDAQ · Health Care
$3.39as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$3.15
Industry
Biotechnology: Pharmaceutical Preparations
About HCWB
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- hcwbiologics.com/
Fundamentals
- Market cap
- $6.19M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-8.07
- Dividend yield
- —
- Beta
- 2.39
- Avg. volume
- —
52-week range
$1.5$39.96
How HCW Biologics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 31, 2026 · via SEC EDGAR / Finnhub
HCW Biologics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HCWBHCW Biologics Inc. Common Stock$3.39▲ 6.94%Market cap $6.19MP/E —$1.5$39.96
- APVOAptevo Therapeutics Inc. Common Stock$2.36▼ 2.48%Market cap $6.18MP/E 0.00$2.3$48.78
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.45▼ 1.03%Market cap $6.27MP/E —$1.31$8.34
- PULMPulmatrix Inc. Common Stock$1.51▼ 0.66%Market cap $6.06MP/E —$1.16$5.5
- XBIOXenetic Biosciences Inc. Common Stock$3.98▲ 1.66%Market cap $6.53MP/E —$1.9$13.93
- ALZNAlzamend Neuro Inc. Common Stock$1.66▼ 0.30%Market cap $6.61MP/E —$0.84$2.68
- IMNNImunon Inc. Common Stock$1.58▼ 1.25%Market cap $6.64MP/E —$1.47$6.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HCWB HCW Biologics Inc. Common Stock | $6.19M | — | $3.39 | ▲ 6.94% | $1.5$39.96 |
| APVO Aptevo Therapeutics Inc. Common Stock | $6.18M | 0.00 | $2.36 | ▼ 2.48% | $2.3$48.78 |
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.27M | — | $1.45 | ▼ 1.03% | $1.31$8.34 |
| PULM Pulmatrix Inc. Common Stock | $6.06M | — | $1.51 | ▼ 0.66% | $1.16$5.5 |
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $3.98 | ▲ 1.66% | $1.9$13.93 |
| ALZN Alzamend Neuro Inc. Common Stock | $6.61M | — | $1.66 | ▼ 0.30% | $0.84$2.68 |
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.58 | ▼ 1.25% | $1.47$6.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral Infectionsbenzinga · 8/25/2026
- HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral InfectionsBenzinga · 8/25/2026
- Which stocks are moving before the opening bell on Friday?ChartMill · 8/21/2026
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · 8/18/2026
- Watching HCW Biologics; Traders Circulate HCW Biologics Peer-Reviewed Journal Of Virology Study Showing HCW9218 Demonstrates Potential To Enhance Immune Responses Against HIV-1, Titled "Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity"Benzinga · 8/14/2026
- HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control IdentifiedBenzinga · 8/14/2026
Insider Activity
Insider Actions →Acquired
344.7K
Disposed
0
- Hing C. Wong · July 29, 2026 · Buy23.2K @ $2.59
- Lee Flowers · July 29, 2026 · Buy7.7K @ $2.59
- Scott T. Garrett · July 29, 2026 · Buy7.7K @ $2.59
- Hing C. Wong · May 22, 2026 · Buy113.9K @ $1.41
- Rebecca Byam · May 22, 2026 · Buy14.2K @ $1.41
- Scott T. Garrett · May 22, 2026 · Buy177.9K @ $1.41
See the full, filterable feed with live charts on the MarketWall dashboard.